Teva Pharmaceutical Industries' (TEVA) Buy Rating Reiterated at Canaccord Genuity


Several other research firms have also recently weighed in on TEVA. Guggenheim reiterated a "buy" rating and issued a $80.00 price target on shares of Teva Pharmaceutical Industries in a report on Tuesday, April 19th.



from Biotech News